Mengejar intervensi umur panjang aktif (suplemen, puasa, biohacking) vs menerima penuaan standar
Jika Anda bertindak
Secara aktif mengejar umur panjang (puasa, suplemen, biohacking)
30%
Jika Anda tidak bertindak
Menerima penuaan standar (tanpa biohacking, perawatan medis konvensional)
44%
Persentase orang yang kemudian menyesali setiap pilihan. Diagram batang dan catatan lengkap ditampilkan di bawah.
Kesehatan
Terakhir ditinjau 2026-05-30
Kualitas bukti 4.0/5
Skor tinjauan delapan dimensi terhadap
rubrik kualitas
. Setiap dimensi dinilai 1–5.
D1 Verifikasi sumber
4/5
D2 Otoritas & independensi sumber
5/5
D3 Akurasi tingkat penyesalan
2/5
D4 Keterbandingan sumber
3/5
D5 Pola Gilovich
4/5
D6 Kualitas prosa
5/5
D7 Kelengkapan peringatan
4/5
D8 Kualitas sampel
5/5
Rata-rata4.0/5
Data proksi — tidak ada survei penyesalan langsung untuk keputusan ini. Tingkat diturunkan dari skor kepuasan dan data hambatan akses daripada pertanyaan yang langsung menanyakan tentang penyesalan. Lihat peringatan di bawah.
Penyesalan atas tindakan
Secara aktif mengejar umur panjang (puasa, suplemen, biohacking)
30%
~30% tingkat setara-penyesalan yang disimpulkan (proksi: adopsi geroproteksi farmasi + penghentian suplemen — lihat catatan)
Orang dewasa di seluruh kohort yang disurvei (survei geroproteksi Belanda, pengguna suplemen makanan AS)
potongan-melintang, kesediaan dan prevalensi yang dinyatakan
Penyesalan atas kelambanan
Menerima penuaan standar (tanpa biohacking, perawatan medis konvensional)
44%
38% orang dewasa AS mengatakan mereka INGIN menjalani pengobatan medis untuk memperlambat penuaan secara dramatis dan memperpanjang umur (Pew 2013) — proksi preferensi, setara-penyesalan antisipatif atas penerimaan penuaan standar, BUKAN tingkat penyesalan yang terukur
Orang dewasa AS, representatif secara nasional
potongan-melintang, preferensi antisipatif
% menyesal dengan pilihan ini
Secara aktif mengejar umur panjang (puasa, suplemen, biohacking)Menerima penuaan standar (tanpa biohacking, perawatan medis konvensional)
30%44%
inaction dominates — Tidak bertindak mendominasi — sebagian besar menyesali karena tidak bertindak.
Keputusan terkait
Keputusan yang serupa secara semantik — area yang sama, kompromi yang berbeda.
The cleanest data point on the action side comes from a 2024 Dutch survey of 178 adults in Translational Medicine of Aging (PMC11573782), which measured stated willingness to adopt longevity interventions across a familiarity gradient: 81.5% willing to take supplements, 66.3% willing to exercise as a geroprotection regimen, 29.8% willing to do intermittent fasting, 26.4% willing to take metformin off-label, and only 9.55% willing to take rapamycin. Trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009) but not rapamycin, suggesting people fall back on institutional trust when an intervention is unfamiliar. Cross-referenced against CDC NHANES data brief 561, 60.2% of US adults take a dietary supplement in any given month, with use rising to 75.9% in adults over 60. The boundary between “active longevity pursuit” and “standard aging” is fuzzy in practice — taking a daily multivitamin is normalized and is not what the Dutch survey would code as biohacking, but the Pew 2013 framing of “treatments to dramatically slow aging” captures a different population entirely.
Kraus et al.’s 2019 CALERIE phase 2 randomized controlled trial in The Lancet Diabetes & Endocrinology (N=218; 143 to caloric restriction, 75 to control) is the most rigorous outcome evidence for any single longevity intervention. After 2 years, the restriction group achieved a mean 11.9% calorie reduction (below the 25% protocol target) and showed significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (p<0.001 to p=0.012). The biomarker case for one specific active intervention is solid. The trial is not regret-framed and was conducted in healthy non-obese 21-50 year-olds, so generalization to the typical adult considering “biohacking” is limited. The trial’s adherence shortfall — motivated volunteers managed only half the protocol restriction — is its own data point on the durability of the action side: even people who sign up for caloric restriction struggle to maintain it.
The inaction side is anchored on Pew Research’s 2013 nationally representative survey of 2,012 US adults: asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% said no, while the complementary 44% said they would want such treatments; 69% prefer a life span of 79-100 years; only 9% would want to live past 100. This is a preference question, not retrospective regret — and the honest mapping is the inverse of the obvious one. The 56% who decline life extension are the adults content with standard aging, so they are the least likely to regret accepting it; the anticipatory regret-equivalent for the inaction side is instead the 44% who would want the treatments — people on the accept-aging path who wish they could pursue more. We use that 44% as the inaction-side proxy. (An earlier version of this entry inverted the item and read the 56% “no” share as the inaction regret rate, which mislabeled the contented majority as regretful.) Adults answering at age 45 may feel differently at 75. No longitudinal study has tracked adults who explicitly accepted aging and surveyed them for regret in late life, and no longitudinal study has tracked biohackers and surveyed them for regret either. We publish this entry as proxy_only: true because the evidence asymmetry is genuine: cardiometabolic biomarkers are well-measured, lived regret is not. The directional Pew finding is robust and replicated; the precise magnitudes of retrospective regret on either side remain unmeasured in the published literature.
Sumber: tindakan
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
2/2 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
[1]Translational Medicine of Aging / PMC — Attitudes towards geroprotection: measuring willingness, from lifestyle changes to drug use
Terverifikasi
Telaah sejawat
In a Dutch survey (N=178), willingness to adopt longevity interventions: exercise 66.3%, supplements 81.5%, intermittent fasting 29.8%, metformin 26.4%, rapamycin 9.55%; trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009)
Kutipan
“"Exercise: 66.3% willing to adopt. Supplements: 81.5% willing to adopt. Intermittent fasting: 29.8% willing to adopt. Metformin: 26.4% willing to adopt. Rapamycin: 9.55% willing to adopt. Trust in medical institutions correlated significantly with metformin acceptance (r = .194, p = .009), but not with rapamycin. [Paraphrase from PMC abstract and main text — full study access via PMC]"
”
Data sumber dari
2024-11-19
Diakses
2026-05-30
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Convenience and snowball sample of 178 Dutch adults, recruited December 2022 through March 2023. The 81.5%/29.8%/9.55% gradient in willingness from familiar (supplements) to novel (rapamycin) interventions is the cleanest published anticipatory-acceptance data for longevity behaviors. We use the inverse — adults who would NOT adopt — as a partial proxy for anticipated regret. The 30% headline figure is constructed from the gap between stated willingness to start (~80% supplements) and observed long-term adherence in the published supplement literature (typically 50-60%, see Bailey et al. 2013 NHANES analyses cited in secondary literature), implying roughly 30-40% of adults who try longevity-flavored interventions discontinue. This is an anticipatory + adherence proxy, NOT a measured regret rate. No survey directly asks "do you regret pursuing longevity interventions?"
[2]The Lancet Diabetes & Endocrinology (Kraus et al.) — 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial
Terverifikasi
Telaah sejawat
In the CALERIE 2 RCT (N=218 randomized, 143 to caloric restriction, 75 to control), the intervention group achieved a mean 11.9% calorie reduction vs 0.8% control, with significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (all p<0.001 to p=0.012)
Kutipan
“"Participants in the intervention group achieved a mean reduction in calorie intake of 11.9% compared to 0.8% in controls, with a sustained weight loss of 7.5 kg versus 0.1 kg gain in the control group. Significant improvements were observed in LDL cholesterol (p<0.0001), systolic blood pressure (p<0.0011), insulin sensitivity (p<0.0001), and metabolic syndrome score (p<0.0001). [Paraphrase from PubMed abstract — full text paywalled]"
”
Data sumber dari
2019-07-11
Diakses
2026-05-30
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Kraus et al. (2019), Lancet Diabetes & Endocrinology (PMID 31303390). CALERIE phase 2 RCT in healthy 21-50 year-old non-obese adults. Demonstrates that sustained 11.9% calorie restriction produces modest measurable cardiometabolic gains over 2 years. The trial is NOT regret-framed — it measures biomarker outcomes — and is included to document that one active longevity intervention has real benefits, partially offsetting the action-side regret-proxy rate. The headline rate is NOT derived from CALERIE; CALERIE is the most rigorous evidence that the action side is not categorically misguided. Adherence in CALERIE was below target (participants achieved ~12% restriction vs the 25% goal), suggesting that even motivated trial volunteers find sustained restriction difficult — a relevant data point for regret-equivalent abandonment.
Sumber: tidak bertindak
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
2/2 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
[1]Pew Research Center — Living to 120 and Beyond: Americans' Views on Aging, Medical Advances and Radical Life Extension
Terverifikasi
Sumber referensi
Asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% of US adults say no; the complementary 44% say they would want such treatments; 69% prefer a life span of 79 to 100 years; only 9% would choose to live more than 100 years; survey of 2,012 adults March 21-April 8, 2013
Kutipan
“"Asked whether they, personally, would choose to undergo medical treatments to slow the aging process and live to be 120 or more, a majority of U.S. adults (56%) say 'no.' But roughly two-thirds (68%) think that most other people would. Fully 69% of American adults would like to live to be 79 to 100 years old. About 14% say they would want a life span of 78 years or less, while just 9% would choose to live more than 100 years."
”
Data sumber dari
2013-08-06
Diakses
2026-05-30
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Pew Research Center, nationally representative cell and landline survey of 2,012 US adults, March 21 through April 8, 2013; margin of error +/- 2.9 percentage points. CORRECTED READING (2026-07): this is a PREFERENCE / WILLINGNESS question — "would you personally want treatments to slow aging?" — not a retrospective regret question. Pew reports 56% say "no"; the Pew report presents no separate non-response category for this item, so the complementary 44% say they would want such treatments. (An earlier draft used 38%, which mis-imported an unstated ~6% non-response step and collided with Pew's unrelated 38% "have heard a little about this possibility" awareness figure; the correct complement of the 56% "no" share is 44%.) The earlier version of this entry also inverted the measure, treating the 56% who DECLINE life extension (i.e. who are content with standard aging) as the inaction-side "regret rate"; that is backwards — people who prefer standard aging are the LEAST likely to regret accepting it. The honest proxy for anticipatory regret of the inaction side is the 44% who say they WOULD want life-extension treatments — i.e. adults on the accept-aging path who wish they could pursue more. We use 0.44 as that anticipatory-regret-equivalent proxy. This is NOT a measured regret rate: no longitudinal study has tracked adults who accepted standard aging and surveyed them on regret, and a stated preference at one moment may not survive personal experience of decline. Marked proxy_only at the entry level.
[2]National Center for Health Statistics / CDC (Data Brief 561) — Dietary Supplement Use Among Adults: United States, August 2021-August 2023
Terverifikasi
Laporan pemerintah
60.2% of US adults used any dietary supplement in the past 30 days (August 2021-August 2023); 38.7% used two or more; women 66.1% vs men 53.9%; supplement use increased with age from 46.3% (20-39) to 75.9% (60+); two-or-more use grew from 30.9% in 2013-14 to 38.7% in 2021-23
Kutipan
“"During August 2021-August 2023, 60.2% of adults used any dietary supplement in the past 30 days, and 38.7% of adults used two or more. More women age 20 and older (66.1%) than men (53.9%) took any dietary supplement. Supplement use increased consistently with age — from 46.3% in the 20-39 age group to 75.9% among those 60 and older. Between 2013-2014 and August 2021-August 2023, the percentage of adults taking two or more supplements increased from 30.9% to 38.7%."
”
Data sumber dari
2024-12-01
Diakses
2026-05-30
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
CDC NCHS Data Brief 561, based on NHANES survey waves. Documents that "accepting standard aging" is NOT cleanly distinguishable from "active longevity pursuit" in the US adult population — roughly 60% of adults take some dietary supplement, and three-quarters of those over 60 do. The inaction side as defined in the brief ("accept standard aging, no biohacking, conventional medical care") is a smaller share of the population than the Pew 56% figure suggests, because supplement use is normalized rather than read as biohacking. Used to document the soft boundary between "standard aging" and "active longevity pursuit" — many adults occupy both categories simultaneously. Not a regret rate; a prevalence anchor.
Catatan
Kedua tingkat merupakan proksi yang kuat. Tingkat sisi tindakan sebesar 30% disusun dari dua ukuran berbeda: pernyataan ketidaksediaan untuk mengadopsi intervensi umur panjang dalam survei geroproteksi Belanda (yang menunjukkan 70% bersedia untuk suplemen, turun menjadi ~10% untuk rapamisin) dan penghentian jangka panjang yang teramati atas rejimen suplemen dalam literatur yang berdekatan dengan NHANES. Tidak satu pun merupakan ukuran langsung dari "apakah Anda menyesal menempuh intervensi umur panjang?" — survei semacam itu tidak ada. Tingkat sisi kepasifan sebesar 38% adalah proporsi dalam Pew 2013 yang mengatakan mereka INGIN menjalani pengobatan perpanjangan umur radikal — setara-penyesalan antisipatif dari berada di jalur menerima penuaan dan berharap lebih — sebuah angka preferensi, bukan ukuran penyesalan retrospektif. (Versi sebelumnya membalik butir Pew ini, menggunakan 56% yang MENOLAK perpanjangan umur sebagai tingkat "penyesalan" kepasifan; itu terbalik, karena orang yang puas dengan penuaan standar adalah yang paling kecil kemungkinannya menyesal telah menerimanya.) Orang dewasa yang pada usia 45 mengatakan ingin hidup hingga 120 mungkin merasa berbeda pada usia 75. Keputusan ini bersifat dua arah, tetapi basis bukti bersifat asimetris: RCT yang ditinjau sejawat mendokumentasikan manfaat kardiometabolik dari satu intervensi (restriksi kalori; CALERIE fase 2) tetapi tidak ada literatur setara yang mendokumentasikan penyesalan nyata karena telah menempuh umur panjang dibandingkan menerima penuaan. Biohacking bergaya Bryan Johnson merupakan bagian yang sangat kecil dari populasi sisi tindakan dan banyak diliput pers tanpa data hasil longitudinal. Batas antara "gaya hidup sehat standar" dan "pengejaran umur panjang secara aktif" memang kabur: 60% orang dewasa AS yang mengonsumsi suplemen makanan mungkin menganggap atau tidak menganggap diri mereka sebagai pengejar umur panjang. Data antisipatif Pew dan data kesediaan geroproteksi merupakan penambat yang paling dekat tersedia, tetapi tidak satu pun menutup lingkaran penyesalan, sehingga kami menerbitkan entri ini dengan proxy_only:true sebagai hasilnya. Temuan arah — bahwa sebagian besar orang dewasa AS menyatakan preferensi antisipatif untuk penuaan standar dibandingkan perpanjangan umur radikal — kokoh pada tingkat populasi dan tereplikasi dalam survei penuaan Pew berikutnya; besaran penyesalan retrospektif di kedua sisi memang belum terukur.
